Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

May 9, 2023

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 45 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning. I'm Tania, and I'll be the conference operator for today. I'd like to welcome all of you to Cronos Group's 2023 First Quarter Earnings Conference Call. This call is being recorded today. At this point, I'll hand things over to Shayne Laidlaw from Investor Relations. Please go ahead.

Shayne Laidlaw

executive
#2

Thanks, Tania. And thanks to everyone for being here as we go through Cronos' financial and business results for the first quarter of 2023. With me today are Mike Gorenstein, our Chairman, President and CEO, and James Holm, our CFO. This morning Cronos put out a news release with our financial results, and it's been filed on our EDGER and SEDAR profiles. That information, along with the prepared remarks, will also be posted on our website under Investor Relations. Before I hand the call to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Those forward-looking statements rest on management's current expectations and assumptions, which are subject to risks and uncertainties that could cause actual results to differ materially from what those forward-looking statements project. The factors that could cause actual results to differ materially from expectations are detailed in the earnings materials and our SEC filings available on our website, and any forward-looking statements made during this call are qualified in their entirety by those documents. Information about non-GAAP financial measures, including reconciliations to U.S. GAAP, can also be found in the earnings materials available on our website. Finally, throughout this conference call we'll be making statements regarding market share information.

Shayne Laidlaw

executive
#3

And unless otherwise noted, every market share figure comes from Hifyre. We'll now deliver our prepared remarks, and after that we'll open things up for a question-and-answer session. With that, I'll hand things over to Cronos' Chairman, President and CEO, Mike Gorenstein.

Mike Gorenstein

executive
#4

Thanks, Shayne, and good morning, everyone. Continuing from the strategic realignment we made in 2022, our strategy for 2023 centers on bringing innovative borderless products to market, lifting the gross margin across the whole business, and taking costs out of the P&L as we work toward becoming cash flow positive in 2024. On our previous earnings call, we disclosed an extra $10 million to $20 million in projected operating expense savings for 2023. I'm pleased to say we're on track to hit the top end of that range. That comes after we exceeded our 2022 savings by roughly $29 million against a target of $20 million to $25 million. James will cover the financial results in greater detail in his remarks, but I'd like to speak to the better trajectory of our gross margin. 2022 was a transformative year for Cronos, and it left us on stronger footing for the future. Given, however, the quarter-to-quarter swings in our gross margin performance, which stem from the timing of certain activity tied to intended changes at the Peace Naturals Campus, we prefer to view the year in totality. As a reminder, our gross margin for full year 2022 came in at 13%, though we finished the year in Q4 with a gross margin of negative 1%.

Mike Gorenstein

executive
#5

Moving on to Q1, on a consolidated basis our gross margin came in at 12%. Now that we've firmed up the choice to remain at the Peace Naturals Campus and have restructured the business so our supply chain runs as efficiently as possible, we plan to carry that momentum forward and deliver a steadier gross margin that shows improvement over the Q1 figure as the year goes on. We're also sharply focused on innovation that adds to margin, so we can further diversify what we sell toward higher-margin derivative offerings — among them our edibles, which hold the number one ranking. In Canada during the first quarter, we kept carrying out our strategy of building a strong portfolio of borderless products, with the highlight being a number of new launches in key categories including pre-rolls and vapes. Our Spinach brand is the sole brand ranked in the top 10 for market share across every category it takes part in, namely flower, pre-roll, vapes and edibles. Our award winning Spinach gummies rose to become the number one gummy in Canada in Q1. Spinach ended the quarter holding a 15.3% market share in the edibles category, with retail sales up 49% year-over-year against category growth of 25%. Looking at gummies alone, Spinach's market share stood at 21.9%. We're delighted that our gummies have come to play such an essential role in the lives of so many adult consumers, and we want to thank them for their brand loyalty and their enthusiasm for our products.

Mike Gorenstein

executive
#6

Beating the leading U.S. brand in Canadian edibles only strengthens our belief that this platform travels across borders and can succeed in any market. Even with that solid showing, chewable extracts have weighed on the edibles segment — these are items that claim to exploit a regulatory gap so they can be sold with more potency per pack than compliant edibles allow. Health Canada has lately told producers these products are misclassified as cannabis extract, and it has set out measures to pull them from the market. As a point of reference, 4 of the top 10 edibles are non-compliant edible extracts, so we expect a stronger second half from our edible portfolio. On vapes, we posted a 4.4% share in Q1, a gain of 230 basis points versus a year ago, moving up to seventh place. We'll carry that momentum into '23 by continuing to add flavor-forward profiles and rare cannabinoids to our base, pushing innovation while staying ahead with the winning formulations consumers enjoy throughout the portfolio. Under the Spinach FEELZ brand we introduced a new Mango Kiwi Haze CBC vape at 32% THC and 5% CBC. Our CBC gummies have done well in the early stage of their Canadian launch, and we're eager for consumers to experience CBC in vape form.

Mike Gorenstein

executive
#7

We also rolled out the Spinach FEELZ BlackBerry Kush THC: CBN vape, and that product has played a part in driving our retail sales in the category up an outsized 155% year-over-year in Q1, compared with category growth of 22% over that same period. Among cannabis market segments, pre-rolls rank among those expanding most quickly. During the first quarter, the category rose 38% year-over-year, and infused pre-rolls made up roughly 24% of dollar share within pre-rolls over that same stretch. Taking what we achieved in edibles as a template for other formats, Cronos kept raising and distinguishing the consumer experience by launching a lineup of infused pre-rolls that draw on our best-in-class potent genetics, on flavor-forward and terpene-rich formulations, and on rare cannabinoids that are sought after. In Q1, we introduced two pre-rolls centered on rare cannabinoids: the Spinach FEELZ Mango Kiwi Haze THC: CBC pre-roll and the Spinach FEELZ BlackBerry Kush THC: CBN pre-roll. After we revamped the portfolio last year, Spinach pre-rolls have picked up market share, climbing to the eighth most popular brand in Q1, up from 16 in Q4. That leaves us with the right vape and pre-roll portfolio in place, along with the recent launches of four infused pre-roll offerings, three of which use rare cannabinoids.

Mike Gorenstein

executive
#8

We intend to leverage that momentum so we can keep gaining share in this category that matters so much to us. We ended the first quarter holding onto our number three position in flower, which works out to 5.2% of retail sales. In Canada, flower sales remain heavily concentrated in 28-gram bags, which account for nine of the top 10 SKUs. Even so, we keep protecting our share across all pack sizes, led by our 3.5-gram GMO cookie SKU and our 28-gram wedding cake. GrowCo stayed strong during Q1. GrowCo posted preliminary unaudited revenue of roughly $3.2 million from non-Cronos customers. On top of that, the credit facility Cronos extended to GrowCo earlier has $73.2 million outstanding right now, after GrowCo repaid $0.7 million of principal in Q1. GrowCo also made a $5.5 million interest payment during Q1. GrowCo's solid financial results, which generate equity pickup, interest payments and loan repayment for Cronos, are an essential piece of our overall financial picture. Now to Israel: growth in the medical cannabis sector decelerated in Q1, pushed by geopolitical issues and disruptions from government appointments, and that has produced several changes at the Health Ministry, slowing patient permit approvals and intensifying competitive activity.

Mike Gorenstein

executive
#9

We’re more hopeful again after the latest update from the Israeli Health Ministry that regulatory changes could affect the way medical patients get cannabis. A government committee has advised Israel to move from the existing system—where personal patient licenses are issued through a more complicated process—to issuing prescriptions through public health care services. Under the new proposal, getting a cannabis prescription would become simpler, and that could raise patient numbers by several times. As a reminder, Israel currently has roughly 125,000 medical patients, which is only 1.3% of the population. Compare that with a mature medical market such as Florida in the U.S., where 3.7% of the population is approved to buy medical cannabis. If Israel were to reach 3.7% of its population, that would equal 346,000 patients and a tripling of the current market size. We believe that is a realistic scenario and possible over the next couple of years, particularly because the change would create a favorable regulatory environment, including pharmacy distribution and a federally legal jurisdiction. We are confident in the long-term potential of our position in the Israeli market, since it remains one of the world’s largest federally legal medical programs today.

Mike Gorenstein

executive
#10

We hold the market's best-performing brand, Peace Naturals, and we keep putting money into growth here. In the U.S., our move out of the beauty category is nearly finished. And we're pressing ahead by bringing Lord Jones back to its origins as an adult use brand with high quality cannabinoid products. We're building a collection of borderless products backed by strategic infrastructure and global partnerships, along with an industry leading balance sheet that lets us execute effectively in any market. With that, I'll hand things over to James to walk you through our financials.

James Holm

executive
#11

Thanks, Mike. And good morning, everyone. I'll now walk through our first quarter 2023 results compared with the prior year period. The company reported consolidated net revenue of $20.1 million in the first quarter, a 20% decrease from the prior year period. Constant currency consolidated net revenue decreased by 14% to $21.7 million. The revenue change is primarily driven by lower cannabis flower sales in the rest of world segment and a decline in the U.S. segment due to its strategic repositioning. Consolidated results were additionally impacted by the weakened Canadian dollar and Israeli shekel against the U.S. dollar during the current period. These results were partially offset by growth in cannabis extract sales in Canada. Consolidated gross profit in the fourth quarter was $2.4 million, equating to a 12% gross margin, representing a $4.5 million decline from the prior year period. The decline was primarily driven by reduced gross profit in the rest of world segment due to lower cannabis flower sales in Israel and adverse price mix shift and cannabis flower sales in Canada, increased returns and a reduction in gross profit in the U.S. segment. These results were partially offset by higher cannabis extract sales in Canada with a higher margin profile than other product category and lower cannabis biomass costs.

James Holm

executive
#12

As Mike said, 2022 results fluctuated from one quarter to the next because of how we realigned the business, and that makes the gross margin comparison for Q1 tough. Keeping that in mind, if you look at the full year 2022, when gross margin was positive 13%, and at the sequential move from Q4, with a negative 1% gross margin, to Q1 2023, when gross margin was positive 12%, encouraging signs of improvement and stability are visible, and we plan to build on that momentum through 2023. Consolidated adjusted EBITDA for the first quarter came in at negative $16.8 million, which is a $2.1 million improvement over the prior year. That gain came mainly from lower general and administrative and research and development expenses. As Mike said, we are on track toward the high end of the $10 million to $20 million in operating expense savings for 2023 that we announced previously. Now to our reporting segments. For the rest of world segment, first quarter net revenue was $19.5 million, down 14% from the prior year period. Constant currency net revenue for the rest of world segment fell 7% to $21 million. The revenue change came mainly from lower cannabis flower sales in Israel, caused by heightened competitive activity, a slowdown in patient permit authorizations, and political unrest.

James Holm

executive
#13

In Canada, sales took a hit from an unfavorable shift in price mix within the flower category, which pushed excise tax payments up as a share of revenue and also raised returns. Those results were partly offset by growth in cannabis extracts in Canada, fueled by edibles and vapes. For the rest of the world segment, gross profit in the first quarter came to $2.9 million, which is a $3.8 million drop from the prior year period. The main driver of that decrease is lower cannabis flower sales in Israel, along with unfavorable price mix shifts in the Canadian flower category caused by consumers moving to 28-gram bags from 3.5-gram box. Partly offsetting these results are higher cannabis extract sales in Canada, which carry a higher margin profile than other product categories, as well as lower cannabis biomass costs. Adjusted EBITDA for the rest of the world segment in the first quarter was negative $10 million, a $6.6 million decline from the prior year period. The drop versus the prior year was mainly driven by a decline in gross profit. Moving to the U.S. segment, we reported net revenue of $650,000 in the first quarter, a 72% decrease from the prior year period. The year-over-year decline was driven by a reduction in promotional spending and SKU rationalization stemming from the strategic realignment of our U.S.

James Holm

executive
#14

On the business side, gross profit for the U.S. segment in the first quarter came in at negative $550,000, which is a $760,000 decline compared with the prior year period. That year-over-year decrease was mainly the result of lower sales volumes along with higher inventory reserves. Adjusted EBITDA for the U.S. segment in the first quarter was negative $2.9 million, an improvement of $4.2 million versus the prior year period. The gain compared with the prior year came primarily from a reduction in sales and marketing and general and administrative expenses. Moving to the balance sheet, the company finished the quarter with roughly $836 million in cash in short term investments. Beyond maximizing the return on our cash, we received an interest payment on our GrowCo senior secured loan of $5.5 million, which, together with regular quarterly principal payments of $0.7 million, brought total cash paid by GrowCo to Cronos to $6.2 million in Q1. Having the best balance sheet in the cannabis industry lets us make calculated strategic fit, while we stay steadfastly focused on reducing cash burn. Last year, we made significant strides to reduce spending and improve our cash burn rate, and in February we committed to an additional $10 million to $20 million in savings across operating expense categories in 2023, and we are currently tracking towards the high end of that range.

James Holm

executive
#15

Turning now to cash flow — if we adjust for the roughly $32.8 million cash outflow for income taxes payable tied to the onetime Altria warrants relinquishment, then free cash flow for Q1 2023 would have come in at negative $15.7 million, which is a 55% improvement year-over-year. We expect to recover the majority of that tax payment connected to the onetime Altria warrant relinquishment across the next three years. Finally, for the rest of fiscal year 2023, we expect cash flow — defined as the net change in cash and cash equivalents, excluding the impact from purchasing proceeds of short term investment — to have declined by under $25 million. The company also anticipates positive cash flow in 2024. That better cash flow trajectory will come from, among other items, net revenue of $100 million to $110 million for full year 2023, continued gross margin improvement, efforts to reduce operating expense, and anticipated interest income of $30 million for the remainder of fiscal year 2023. With that, I'll hand it back to Mike.

Mike Gorenstein

executive
#16

Thank you, James. Thanks to the hard work our employees put in to bring best-in-class borderless products to market, we are winning in Canada and Israel. Among all the categories our Spinach brand competes in — flower pre-rolls, vapes and edibles — it is the only brand holding a top 10 market share position in every one. We are confident that as regulations change, we will rank among the best positioned cannabis companies to capture additional market share in any market. Before we get into questions, I want to level set what sits under the Cronos umbrella and where things stand today. We closed Q1 with $836 million in cash and equivalents and zero debt. And we generated $11.2 million in interest income, with an anticipation to generate an additional $30 million interest income for the remainder of 2023. Our Spinach brand has the following market share ranks for Q1. Overall Spinach is the number three cannabis brand and is number one in edibles, number three in flower, number eight in pre-rolls and number seven in vapes. We have a leading medical brand, Peace Naturals in Israel, with close to $5 million in net revenue in Q1, with a 6.3% stake in PharmaCann, one of the largest private U.S.

Mike Gorenstein

executive
#17

Right now, we're carrying MSOs of $49 million on our books. In Vitura — a top publicly traded Australian medical cannabis provider — we hold a stake of roughly 10%, and as of the close of Q1 that was worth about $13.8 million. Toronto's GrowCo is half-owned by us — 50% of the equity — and it's profitable; in Q1 it paid $6.2 million in principal and interest. When the quarter ended, our combined loans to GrowCo and its partners had a remaining balance of about $87 million. We hold real estate and several licensed facilities, all unencumbered. And finally — certainly not least — we have a worldwide exclusive partnership with Altria. As of yesterday's market close, Cronos had a market cap of roughly $780 million and an enterprise value of about negative $56 million. With that, I'll open the line for questions.

Operator

operator
#18

Absolutely. <<operator_script>> The first question comes from John Zamparo at CIBC. Your line is open.

John Zamparo

analyst
#19

Thank you, and good morning. I'd like to begin with Israel. We're hoping for a bit more detail on that front, and I apologize if I missed it. But I'm curious: what do you believe that market has to do in order to return to growth? What are you observing when it comes to competition? And in the past, you've enjoyed a degree of protection relative to your peers in Israel thanks to your brand? I'm wondering what specifically would need to change for you to feel perhaps more optimistic about Israel in the back half of the year?

Mike Gorenstein

executive
#20

Absolutely, John, thank you. The main factor we're observing in Israel when it comes to competition is really tied to growth in patient numbers. There's been political turbulence, and that has significantly held back much of the regulatory progress. That said, there have been announcements — particularly as of late regarding advancements — apologies, regarding regulations that would actually alter how prescriptions get issued, specifically which pharmacies can stock cannabis. What this would do, essentially, is shift away from the current special framework, where patients must go through a whole series of steps that act as obstacles to entering the system, toward treating it like any other controlled substance. As we mentioned during the prepared remarks, we can observe that this would genuinely boost patient numbers by multiples. And if you consider — looking at Q1 of last year, we've seen that whenever a favorable regulatory shift occurs in Israel, you can observe truly, truly swift expansion. And based on the announcements, every indication suggests that this is something achievable during this year. So we're watching that over the coming couple of months, looking toward more in Q4, and I believe that would truly unlock the whole market and bring us back to what we witnessed at the start of last year when it comes to growth.

John Zamparo

analyst
#21

All right, got it. My second question then concerns gross margins—specifically for rest of world. You had a good increase in Q1 compared with Q4, but I'm curious about when, and perhaps we've reached that point already, gross margin and rest of world might more or less level off. I presume there are several variables tied to the changeover back to Stayner. Clearly, that line carries a fair amount of fixed costs, so you can't fully forecast it. That said, have we now arrived at a stage where gross margin ought to more or less steady out, or does that depend on how the back half of the year develops?

James Holm

executive
#22

Hey John, appreciate the question. So I suppose in response, I'd say yes, things are somewhat stable, though we do anticipate additional gains going forward. As you pointed out, we're constantly refining our supply chain, right; we're looking at shifting certain activities back to Stayner, and some of those are underway. So we'd anticipate additional gains as some of those work their way through COGS, and therefore we'd expect potential margin pickups, right, across the rest of the year. But we're kind of returning to a more normalized state compared with a lot of the volatility we're seeing in the prior year.

John Zamparo

analyst
#23

All right, that’s useful — I’ll make sure to relay it. Thanks.

Operator

operator
#24

Please hold briefly while we take the following question. That question comes to us from Andrew Carter at Stifel. Your line is now open.

Andrew Carter

analyst
#25

Hi there, thanks, and good morning. I just wanted to start with the revenue guidance for the year, that 100 to 110. For the rest of the year I'm calculating 19% to 34%, which appears to be 24% to 39% on a constant currency basis when it comes to spot rates. Could you walk us through the cadence of how that phases? And if I caught your response to John's question correctly, you don't really anticipate any improvement in Israel until the fourth quarter. Just help me get my head around that. Thanks.

Mike Gorenstein

executive
#26

Andrew, could you perhaps put that question a different way? In other words, are you asking about when we expect revenue to come in for each period, for each quarter?

Andrew Carter

analyst
#27

Just a bit. I mean, to begin with the $100 million to $110 million in revenue for the year, the back nine has to grow 19% to 34%. And that means constant currency, if my math is right on spot, 24 to 39. So I'm asking, what's the phasing of that revenue growth acceleration? And within that, what about — if I heard John's question right, Israel doesn't improve until the fourth quarter?

Mike Gorenstein

executive
#28

Understood, and that's a fair point. So yes, we have confidence in our revenue guidance of $100 million to $110 million for the full year 2023, and that is what drives part of the second-half improvement you pointed to. Over the past six months we have brought out a meaningful number of new innovations, and we also have a strong pipeline of innovation launches planned for the rest of the year that should help fuel that additional growth. And then we announced today that we are on track to hit the top end of our OpEx savings targets, of $10 million to $20 million. Now all of that works together to drive the overall improvement in cash flow. But we do expect continued revenue improvements, right throughout the duration of the year.

James Holm

executive
#29

To add to that point: regarding Israel in Q4, that is really where you should expect to see an enormous step change and what I would describe as meteoric growth. When we discuss that, our guidance does not depend on the regulatory change. Still, we believe it is more likely than not, and we are very optimistic about it.

Mike Gorenstein

executive
#30

Yes, that would represent extra upside.

Andrew Carter

analyst
#31

Then the second one, just to make sure I understand the first point — in 2024, I believe you mentioned positive free cash flow; is that assumption tied to the interest rates as they stand today? And I suppose, circling back to what you said toward the end of the script, Mike, about where enterprise value sits at the moment — does that turn into an obstacle for what you're attempting here, and more broadly, when equity value is negative enterprise value? Or is the answer simply that you've got sufficient capital to deploy and you'll keep deploying it? Or do you sense some sort of pressure to push the shares in your direction, which would clearly help with M&A? Thanks.

Mike Gorenstein

executive
#32

Absolutely, James — guidance is yours to start with, and after that I'll move on to the balance sheet and where we stand.

James Holm

executive
#33

Yes, and I'm sorry — Andrew, I'm running into some trouble with my connection, so could you rephrase or repeat that question about guidance?

Andrew Carter

analyst
#34

Yeah, on the cash flow guidance for next year — does that assume interest rates stay where they are now, and is it built on your own cash flow projections?

James Holm

executive
#35

Understood. So — no, on interest rates, we are certainly factoring in a fair amount of stability there. Right. That said, there is some room to maneuver, if I can phrase it that way. We are likewise assuming the same qualifying conditions and that there is no meaningful deterioration in the overall economic or regulatory climate. So — although I would note we retain a degree of flexibility across each of those. As a result, we feel quite at ease regarding interest rates. The outlook we have provided is fairly cautious too. So my view is that should material shifts occur, right, then clearly that might affect the guidance.

Andrew Carter

analyst
#36

I want to make this crystal clear one more time. Regarding that positive free cash flow in 2024 — does it rest on core operations alone, or does it factor in an assumption for interest income, somewhat the way interest income is, I believe, contributing $40 million in cash this year?

James Holm

executive
#37

Yeah, let me go into a bit more detail there. What we're discussing is net cash flow, so interest income is part of it. What I'm saying is that this reflects better COGS plus OpEx savings in roughly that $10 million to $20 million band — we're tracking toward the high end of it — along with the improved top line we're projecting across the year, which we called out with the 100 to 110 guidance. And then, clearly, interest would be a meaningful piece of that too.

Mike Gorenstein

executive
#38

Thanks. To address the second part of what you asked, Andrew, I don't see any obstacle there. We believe we've got quite a bit of flexibility, and beyond that, I think it matters, and the moment has come, for us to ensure we're self-sustaining. That's really why being cash flow positive matters to us. That said, it doesn't rule anything out for us — if we spot something accretive, we'll stay opportunistic. Naturally, my inclination will always lean toward whatever adds to cash flow, but in the end we'll keep turning over every stone and hunting for something value accretive rather than just depending on interest income. So I still believe we have ample flexibility.

Andrew Carter

analyst
#39

Much appreciated. I'll make sure that gets shared.

Operator

operator
#40

We'll take a brief pause before taking the following question. That next question is from Michael Freeman at Raymond James. Your line is open.

Michael Freeman

analyst
#41

Morning, Mike, James, and Shayne — appreciate you taking our questions. Given that interest payments are becoming, or already have become, a more and more significant element of the sales revenue picture you're seeing right now, I was wondering whether you could walk us through your approach to putting cash to work and generating returns from it.

Mike Gorenstein

executive
#42

Absolutely, Michael, and thank you. So we are always examining ways to get the most out of the cash we have on hand. That means we partner with, I would describe them as large, stable, top-rated financial institutions — particularly given the conditions we're in right now. Our biggest priority is making certain those funds are safe and secure, while naturally also ensuring we get the strongest possible return on them. As a result, we're considering instruments that generally mature in a year or less. To that end, we use a laddering approach with vehicles of three, six, nine, and 12 months. Again, though, the goal is that these are large, stable financial institutions offering top rates of return.

Michael Freeman

analyst
#43

Okay, that’s useful. For my second question: your portfolio of rare and cultured cannabinoids has been spreading across more of your product lines. I’m curious, if we look a couple of years ahead, which products or markets that are still underpenetrated do you think rare cannabinoids could play a meaningful role in?

Mike Gorenstein

executive
#44

Absolutely, that's a really good question. I think as consumer preferences move away from flower and toward derivatives, you're also going to see greater awareness of just what those derivative products actually are. And that's where rare begins to matter. I'd keep highlighting pre-rolls — you've witnessed the broad surge in popularity of infused pre-rolls. And you'll notice as well that many of our launches feature infused pre-rolls, and we still believe that's among the biggest growth categories over the next few years. It's one of the strongest chances to differentiate. And much like what you see with edibles, the further you move beyond flower, the more we think there's a chance to differentiate. So I believe that will be enormous. And we still see plenty of opportunity throughout the remainder of our portfolio in the formats available on the market today when it comes to edibles, vapes, and pre-rolls. And then, looking a few years out, I think there are some interesting things we'll be capable of doing with concentrates, which you haven't seen us launch as of today. But we're — we do believe there's opportunity there.

Michael Freeman

analyst
#45

Okay, that's great. If I could — let me just add one more thing. Regarding pre-rolls and infused pre-rolls in particular, those appeared to be an area Cronos is focused on. I'm curious how you — what you've observed when it comes to pricing in that market? We've heard some discussion about price compression, and I'm wondering how Cronos can — how Cronus will handle that going forward?

Mike Gorenstein

executive
#46

Well, look, I believe pre-rolls represent a really substantial category. And you're going to witness genuine, genuine segmentation in how products get developed. On one end of the spectrum, I think there's a chance to actually offer pre-rolls at a lower price point than flower. You wouldn't need to stress over whether the flower is perfectly manicured, since it's headed into a pre-roll anyway. So you'll have a segment that leans toward value, that leans more on automation. Then on the other end of the spectrum, you move into something closer to a cigar, far more premium, which I believe will command a meaningful premium over flower. So I really think it comes down to innovation. It comes down to grasping precisely what the consumer's needs are and targeting them. That's among the reasons I keep emphasizing why there's such a major opportunity there. But I think you have to ensure you know precisely where your product fits, and have a product very narrowly tailored to that segment in order to win.

Michael Freeman

analyst
#47

All right, thanks a lot. I’ll get back in line.

Operator

operator
#48

We'll take a brief pause before the following question. That question is going to come from Nadine Sarwat at Bernstein. Your line is now open.

Nadine Sarwat

analyst
#49

Hello, and good morning, everyone. I have two questions. First, could you share your observations on pricing in Canada? Are there any indications that we've hit the bottom, or is that oversupplied end market still the dominant factor? Second, you mentioned the strong market share position Spinach has built, particularly in edibles. Looking back a couple of years, people suggested that creating strong brands in cannabis might prove difficult given the risk of the category becoming commoditized. Given your experience in the sector, I'm curious what factors you'd point to as being behind the success of establishing a brand with a strong market share in cannabis. Thank you.

Mike Gorenstein

executive
#50

Absolutely. So, regarding the first thing we're observing—and perhaps one of the more significant contributors to price compression is purely a matter of supply, but it actually relates to excise taxes and the manner in which they're being remitted. And there's a pattern you've picked up on: a really substantial share of the LPs in Canada are in fact not remitting their excise taxes. And I think, considering their capital positions, they're truly using that cost advantage to push prices down even further. So I do believe one of the things that's required—and that I anticipate will occur—is some enforcement around how excise taxes get collected. And broadly speaking, excise tax reform, I think that's something extremely important, very significant for the industry. But we still observe compression, particularly in flower. On the second part of your question, building a brand, I think it's about understanding that you need a product-based focus—you need to have a differentiated product. We have cannabis consumers who are very, very focused on what features the actual product offers. At this stage in the industry, it's less about telling a story, it's less about trying to draw people into a lifestyle community, given the regulations we have around brand building and marketing.

Mike Gorenstein

executive
#51

For us, those are the crucial points—the effect truly, truly is important. Which cannabinoids are combined? I think that explains partly why we're strong in edibles. What we're able to do, offering different experiences with CBN or CBC or CBG leading the way as part of that cocktail, so to speak, is the big differentiator—but flavor too. Flavor is hugely important; that first experience, I think, should be something consumers find enjoyable. And most of the brands are really just focused on cost. So, as with any other product, flavor matters, experience matters.

Nadine Sarwat

analyst
#52

Understood — thanks a lot.

Operator

operator
#53

We'll take the next question in just a moment. And that next question comes from Matt Bottomley at Canaccord. Matt, your line is open.

Matt Bottomley

analyst
#54

Morning, everyone. Appreciate the color so far. Perhaps to build on that, Mike, and the points you made about some of those characteristics. Stepping back a bit further and taking a look at the broader Canadian picture, it still feels like — hard to say — but perhaps just 60% of the total market opportunity that legalizes has actually shifted over to legal channels. Yet markets such as Ontario, along with others, already have retail stores at saturation. And it seems a great deal of the regulatory hurdles around what you folks are able to do are keeping some potential future customers still buying through their illicit channels. That said, is there anything beyond regulatory changes that you believe will bring the overall market TAM in Canada — which appears to have been stuck in the $4 million to $5 million range for quite a while now — forward?

Mike Gorenstein

executive
#55

Yeah, I think so. When you look at those regulatory hurdles, a lot of them are genuinely keeping consumers from getting better pricing and value, particularly on the more premium end. There are things you can keep doing. So you've seen what we're capable of with flower and with the edibles platform. I think if you can deliver a consistent product — something higher end, with a transparent supply chain — there are consumers willing to pay above illicit market prices who will come in. So I think that remains a big opportunity. There's a different perspective when it comes to the highest volume consumer, which is probably a larger portion of TAM. You can see what the regulatory change will do — I spoke a bit about chewable extracts during remarks. And I think what that demonstrates is that if you can offer something with higher potency and a larger pack size, it's closer to the buying habits a legacy consumer in the legacy market has. Consumers will shift really quickly in the market. And so I think making sure you can combine that when you have a better product.

Mike Gorenstein

executive
#56

And what you’ve got is a product that’s clear and is considered a far safer option. For that switch, that matters a great deal. So I believe that keeps moving forward. I also believe that continuing to ensure—across the industry and, in particular, for us as a company—that our supply chain is getting better, and that we can compete more effectively, is going to be a help. Still, in my view, the two biggest drivers will be innovation at the premium end, and possibly pre-rolls being able to generate greater value. After that, it will come down to the major regulatory shift.

Matt Bottomley

analyst
#57

Alright, understood. Thanks. Then one more item from my side: how interested are you in certain U.S. federal headlines, along with Safe Banking, which has been reintroduced? Numerous such items have come up previously. So I believe folks are viewing it with caution. But how significant are headlines of that kind to you when deciding whether to potentially put some of your capital to work? Or do you figure it would need to be more substantial reform — perhaps along the lines of what Joe Biden and the White House are attempting with rescheduling as a whole?

Mike Gorenstein

executive
#58

I'd say safe banking is likely the single most important factor when it comes to making progress. It matters, and in terms of sentiment and capital markets, it functions as a kind of bellwether. As for the big picture, I think it simply demonstrates that we have some form of regulatory catalyst here in the U.S. But when you consider the major things you need — one of the biggest being what you can accomplish in terms of bringing capital markets in and getting some of the larger banks involved — all of that would be resolved through appropriate rescheduling. And in my view, that's an underappreciated piece, and the most significant regulatory news we have in the pipeline. So that's really what I'm looking toward. I believe it's something that's moving. Everyone is focused on safe banking, I know. Whether or not it happens, I won't make a prediction. But as it's currently drafted, I think it's really more a matter of incremental progress.

Matt Bottomley

analyst
#59

All right, I appreciate that rundown.

Operator

operator
#60

We'll take a moment before taking the next question. And that next question comes from Victor Ma at TD Cowen. Victor, your line is open.

Victor Ma

analyst
#61

Hello, and good morning. This is Victor Ma, filling in for Vivien Azer, and thanks for taking our questions. So, to start, if we look back at the Hifyre data, there were some share declines on a sequential basis in vapes as well as edibles. Could you give us any additional detail on that and explain what's behind those trends? And please also speak to how defensible Spinach's product differentiation is. Thank you.

Mike Gorenstein

executive
#62

My apologies — I didn’t catch the final portion of what you asked.

Victor Ma

analyst
#63

I’d just like to make a point about how differentiated Spinach’s product really is.

Mike Gorenstein

executive
#64

Sure. I think the main thing we’ve observed in this area relates to chewable extracts. I believe we were performing quite strongly when it came to defending and winning against that. Then Health Canada made an announcement that basically anyone selling chewable extracts—with four of the top 10 SKUs at present—would be unable to sell at the end of May. And you did see a considerable amount of pantry loading. That could carry on for another few weeks. But since demand has ramped up over a few weeks, my expectation is that we’ll not only recover that share in the back half of the year once that inventory is depleted, but also, with anything we may have lost, I think there’s additional opportunity to gain simply from that shift. And looking longer term in terms of defensibility—and I tend to think about it more offensively—I truly hope the government uses this chance to take a look and see. The world didn’t fall apart with higher potency edibles. It’s something consumers certainly have demand for.

Mike Gorenstein

executive
#65

So we'd be fully prepared, should anything shift there, to launch a put-up compliant offering at the same quality level we currently have in the market. And I think, with certain regulatory changes, we've consistently taken the stance that our innovation spending should be directed toward long-term initiatives, ensuring we handle things properly. That said, we do see that as a substantial moat — product differentiation, differentiated products, will remain. I think we've been fairly steady when it comes to defending on the product front and being able to gain share. So I'd characterize it as a temporary blip. And in the end, the situation surrounding the chewable extract flip is actually more bullish for us than it would be otherwise.

Victor Ma

analyst
#66

Thanks. Could you give us a bit more detail on the share losses in vapes? In that category, I believe share also declined from one quarter to the next.

Mike Gorenstein

executive
#67

Yeah, I think vapes are probably a little more nuanced — it relates to how big the actual vape carts are and their potency, which is an update that we made. And when you make those updates, you can see fairly small fluctuations. And that ties somewhat to what the ordering patterns look like, particularly when you're doing changeovers. But I don't think there's any trend concern there. And I think you'll see that affect us.

Victor Ma

analyst
#68

Thanks a lot, and now for my second question. Regarding Israel, could you say something about the stronger competitive activity in the quarter? Are you noticing heavier discounting on a pro forma basis, and how long-lasting do you expect these competitive moves to be? Thank you.

Mike Gorenstein

executive
#69

Sure. I believe discounts have grown, and consolidation is happening, much like what we saw with market participants in Canada. You're beginning to notice additional consolidation, and you'll see additional businesses leave the market. My sense is that investment capital in Israel is much lower than it was in Canada. And you're seeing additional Canadian businesses attempt to enter Israel. Yet in the end, this is something I think we're, you know, we're accustomed to, something I think we can definitely protect ourselves against. I do believe the largest relief and the largest opportunity ties to a regulatory change. But, as we've witnessed in Canada when access exists, I think opportunity exists, and we've managed to, with our flower products and other innovations, differentiate ourselves and gain share, and they will keep concentrating on Israel.

Victor Ma

analyst
#70

Appreciate the extra detail there. I'll get back in line for questions.

Operator

operator
#71

That brings us to the end of the conference call for today. Thanks for joining us. You can go ahead and disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.